The Home Office do not hold this information.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1561", "label" : {"_value" : "Biography information for Mr Nick Hurd"} } , "answeringMemberConstituency" : {"_value" : "Ruislip, Northwood and Pinner"} , "answeringMemberPrinted" : {"_value" : "Mr Nick Hurd"} , "dateOfAnswer" : {"_value" : "2019-01-17", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-01-17T17:39:12.807Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "1"} , "answeringDeptShortName" : {"_value" : "Home Office"} , "answeringDeptSortName" : {"_value" : "Home Office"} , "date" : {"_value" : "2019-01-16", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "High Rise Flats: Fires"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for the Home Department, what estimate he has made of the number of fires in (a) publicly and (b) privately owned high rise residential blocks in each of the last 20 years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4631", "label" : {"_value" : "Biography information for Sarah Jones"} } , "tablingMemberConstituency" : {"_value" : "Croydon Central"} , "tablingMemberPrinted" : [{"_value" : "Sarah Jones"} ], "uin" : "208350"} , {"_about" : "http://data.parliament.uk/resources/1042203", "AnsweringBody" : [{"_value" : "Department for Environment, Food and Rural Affairs"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1042203/answer", "answerText" : {"_value" : "
Defra intends to provide a summary of responses and the Government response by 7 February as set out on the consultation web page.<\/p>
<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4033", "label" : {"_value" : "Biography information for David Rutley"} } , "answeringMemberConstituency" : {"_value" : "Macclesfield"} , "answeringMemberPrinted" : {"_value" : "David Rutley"} , "dateOfAnswer" : {"_value" : "2019-01-17", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-01-17T17:46:13.467Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "13"} , "answeringDeptShortName" : {"_value" : "Environment, Food and Rural Affairs"} , "answeringDeptSortName" : {"_value" : "Environment, Food and Rural Affairs"} , "date" : {"_value" : "2019-01-16", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Food: Labelling"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "When his Department plans to respond to its consultation entitled Food labelling: amending laws.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1513", "label" : {"_value" : "Biography information for Jo Swinson"} } , "tablingMemberConstituency" : {"_value" : "East Dunbartonshire"} , "tablingMemberPrinted" : [{"_value" : "Jo Swinson"} ], "uin" : "908633"} , {"_about" : "http://data.parliament.uk/resources/1042204", "AnsweringBody" : [{"_value" : "Department for Environment, Food and Rural Affairs"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1042204/answer", "answerText" : {"_value" : "
Ministers regularly meet with the Foreign Secretary to discuss international species conservation issues. Our close working delivered the highly successful Illegal Wildlife Trade Conference in London in October last year, which brought together global leaders to drive forward action to end this despicable trade. Our ban on ivory sales through the Ivory Act is one of the toughest in the world and demonstrates our joint leadership to galvanise action around the world.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4098", "label" : {"_value" : "Biography information for Dr Thérèse Coffey"} } , "answeringMemberConstituency" : {"_value" : "Suffolk Coastal"} , "answeringMemberPrinted" : {"_value" : "Dr Thérèse Coffey"} , "dateOfAnswer" : {"_value" : "2019-01-17", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-01-17T16:14:23.503Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "13"} , "answeringDeptShortName" : {"_value" : "Environment, Food and Rural Affairs"} , "answeringDeptSortName" : {"_value" : "Environment, Food and Rural Affairs"} , "date" : {"_value" : "2019-01-16", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Nature Conservation"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "What recent discussions he has had with the Foreign Secretary on the protection of endangered species.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4498", "label" : {"_value" : "Biography information for Mr Ranil Jayawardena"} } , "tablingMemberConstituency" : {"_value" : "North East Hampshire"} , "tablingMemberPrinted" : [{"_value" : "Mr Ranil Jayawardena"} ], "uin" : "908630"} , {"_about" : "http://data.parliament.uk/resources/1041248", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1041248/answer", "answerText" : {"_value" : "
The Department\u2019s plans to ensure the supply of medicines in the event of the United Kingdom leaving the European Union without a deal have been subject to scrutiny by a number of Parliamentary Committees, including the Public Accounts Committee, the Health and Social Care Committee, the EU Exit Committee and the House of Lords EU Home Affairs Sub-Committee. The Department is also working closely with suppliers, their supply chains, health services and devolved administrations to maintain the continuity of medicines supply in a \u2018no deal\u2019 EU exit scenario.<\/p>
<\/p>
We are unable to publish the list of medicines requested. To reassure participating companies, we have committed to treating all information received confidentially, securely and to using it only for the purposes of the Department\u2019s contingency programme. That means not introducing information about a specific company, medicine or supply route into the public domain.<\/p>
<\/p>
On 23 August 2018, the Department wrote to all pharmaceutical companies that supply prescription-only and pharmacy medicines to the UK that come from, or via, the EU or European Economic Area (EEA), asking them to ensure a minimum of six weeks\u2019 additional supply in the UK, over and above existing business-as-usual buffer stocks, by 29 March 2019. We recognise, however, that certain medicines with short shelf lives, including medical radioisotopes, cannot be reasonably stockpiled. Where these medicines are imported from the EU or EEA, we have asked that suppliers ensure in advance plans to air freight these medicines from the EU in the event of a \u2018no deal\u2019 exit.<\/p>
<\/p>
Additionally, on 7 December 2018, the Department wrote to pharmaceutical companies that supply licensed medicines to the UK from or via the EU/EEA and/or manufacture medicines in the UK, informing them of the updated reasonable worst-case scenario border disruption planning assumptions and asking them about their current transportation routes and their ability to re-route their supply chains if they currently rely on Dover and/or Folkestone.<\/p>
<\/p>
We have received very good engagement from industry who share our aims of ensuring continuity of medicines supply for patients is maintained and that suppliers are able to cope with any potential delays at the border that may arise in the short term in the event of a \u2018no deal\u2019 exit.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1585", "label" : {"_value" : "Biography information for Stephen Hammond"} } , "answeringMemberConstituency" : {"_value" : "Wimbledon"} , "answeringMemberPrinted" : {"_value" : "Stephen Hammond"} , "dateOfAnswer" : {"_value" : "2019-01-17", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "208298"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-01-17T16:27:06.083Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-01-14", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "NHS: Drugs"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, whether his Department's plans to ensure the supply of medicines in the event of the UK leaving the EU without a deal (a) have been or (b) will be subjected to an independent evaluation.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4504", "label" : {"_value" : "Biography information for Wes Streeting"} } , "tablingMemberConstituency" : {"_value" : "Ilford North"} , "tablingMemberPrinted" : [{"_value" : "Wes Streeting"} ], "uin" : "208297"} , {"_about" : "http://data.parliament.uk/resources/1041249", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1041249/answer", "answerText" : {"_value" : "
The Department\u2019s plans to ensure the supply of medicines in the event of the United Kingdom leaving the European Union without a deal have been subject to scrutiny by a number of Parliamentary Committees, including the Public Accounts Committee, the Health and Social Care Committee, the EU Exit Committee and the House of Lords EU Home Affairs Sub-Committee. The Department is also working closely with suppliers, their supply chains, health services and devolved administrations to maintain the continuity of medicines supply in a \u2018no deal\u2019 EU exit scenario.<\/p>
<\/p>
We are unable to publish the list of medicines requested. To reassure participating companies, we have committed to treating all information received confidentially, securely and to using it only for the purposes of the Department\u2019s contingency programme. That means not introducing information about a specific company, medicine or supply route into the public domain.<\/p>
<\/p>
On 23 August 2018, the Department wrote to all pharmaceutical companies that supply prescription-only and pharmacy medicines to the UK that come from, or via, the EU or European Economic Area (EEA), asking them to ensure a minimum of six weeks\u2019 additional supply in the UK, over and above existing business-as-usual buffer stocks, by 29 March 2019. We recognise, however, that certain medicines with short shelf lives, including medical radioisotopes, cannot be reasonably stockpiled. Where these medicines are imported from the EU or EEA, we have asked that suppliers ensure in advance plans to air freight these medicines from the EU in the event of a \u2018no deal\u2019 exit.<\/p>
<\/p>
Additionally, on 7 December 2018, the Department wrote to pharmaceutical companies that supply licensed medicines to the UK from or via the EU/EEA and/or manufacture medicines in the UK, informing them of the updated reasonable worst-case scenario border disruption planning assumptions and asking them about their current transportation routes and their ability to re-route their supply chains if they currently rely on Dover and/or Folkestone.<\/p>
<\/p>
We have received very good engagement from industry who share our aims of ensuring continuity of medicines supply for patients is maintained and that suppliers are able to cope with any potential delays at the border that may arise in the short term in the event of a \u2018no deal\u2019 exit.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1585", "label" : {"_value" : "Biography information for Stephen Hammond"} } , "answeringMemberConstituency" : {"_value" : "Wimbledon"} , "answeringMemberPrinted" : {"_value" : "Stephen Hammond"} , "dateOfAnswer" : {"_value" : "2019-01-17", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "208297"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-01-17T16:27:06.143Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-01-14", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "NHS: Drugs"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, if he will publish (a) a list of medicines for which there is a supply risk in the event of the UK leaving the EU without a deal and (b) a plan to mitigate those supply risks.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4504", "label" : {"_value" : "Biography information for Wes Streeting"} } , "tablingMemberConstituency" : {"_value" : "Ilford North"} , "tablingMemberPrinted" : [{"_value" : "Wes Streeting"} ], "uin" : "208298"} , {"_about" : "http://data.parliament.uk/resources/1041257", "AnsweringBody" : [{"_value" : "Ministry of Defence"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1041257/answer", "answerText" : {"_value" : "
Mefloquine (commercially known as Lariam) is effective in the prevention and treatment of malaria and is licensed for use by the Medicines and Healthcare products Regulatory Agency, which regulates medication in the UK. The current product information for mefloquine states that neuropsychiatric adverse reactions may occur during treatment and includes warnings and precautions to minimise these risks. It also states that such adverse reactions may persist for months, or longer, even after discontinuation of the drug. It has not been established, however, that such adverse reactions may be permanent.<\/p>
<\/p>
Notwithstanding, in September 2016, the Ministry of Defence (MOD) established the mefloquine Single Point of Contact (SPOC) email and telephone line, for both current and former Service personnel who have concerns about their experience of mefloquine. Up to 15 January 2019, the mefloquine SPOC has received the following number of enquiries.<\/p>
<\/p>
Year<\/strong><\/p><\/td> Enquiries from Serving Personnel<\/strong><\/p><\/td> Enquiries from Veterans<\/strong><\/p><\/td> Enquiries from Others<\/strong><\/p><\/td> Total Number of Enquiries<\/strong><\/p><\/td><\/tr> 2016<\/strong><\/p><\/td> 24<\/p><\/td> 33<\/p><\/td> 22<\/p><\/td> 79<\/strong><\/p><\/td><\/tr> 2017<\/strong><\/p><\/td> 3<\/p><\/td> 10<\/p><\/td> 5<\/p><\/td> 18<\/strong><\/p><\/td><\/tr> 2018<\/strong><\/p><\/td> 4<\/p><\/td> 7<\/p><\/td> 6<\/p><\/td> 17<\/strong><\/p><\/td><\/tr> 2019<\/strong><\/p><\/td> 0<\/p><\/td> 1<\/p><\/td> 0<\/p><\/td> 1<\/strong><\/p><\/td><\/tr><\/tbody><\/table> <\/p> Individuals can be referred to the SPOC in a number of different ways, including by Service charities. The MOD does not maintain a record of all such referrals.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/1487", "label" : {"_value" : "Biography information for Mr Tobias Ellwood"}
}
, "answeringMemberConstituency" : {"_value" : "Bournemouth East"}
, "answeringMemberPrinted" : {"_value" : "Mr Tobias Ellwood"}
, "dateOfAnswer" : {"_value" : "2019-01-17", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "208187"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-01-17T16:17:08.88Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "11"}
, "answeringDeptShortName" : {"_value" : "Defence"}
, "answeringDeptSortName" : {"_value" : "Defence"}
, "date" : {"_value" : "2019-01-14", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Armed Forces: Mefloquine"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Defence, when he plans to reach a final conclusion on the effect on veterans' health of the issuing of Larium to them while they were in the Armed Forces.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/252", "label" : {"_value" : "Biography information for Dr David Drew"}
}
, "tablingMemberConstituency" : {"_value" : "Stroud"}
, "tablingMemberPrinted" : [{"_value" : "Dr David Drew"}
], "uin" : "208186"}
, {"_about" : "http://data.parliament.uk/resources/1041258", "AnsweringBody" : [{"_value" : "Ministry of Defence"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1041258/answer", "answerText" : {"_value" : " Mefloquine (commercially known as Lariam) is effective in the prevention and treatment of malaria and is licensed for use by the Medicines and Healthcare products Regulatory Agency, which regulates medication in the UK. The current product information for mefloquine states that neuropsychiatric adverse reactions may occur during treatment and includes warnings and precautions to minimise these risks. It also states that such adverse reactions may persist for months, or longer, even after discontinuation of the drug. It has not been established, however, that such adverse reactions may be permanent.<\/p> <\/p> Notwithstanding, in September 2016, the Ministry of Defence (MOD) established the mefloquine Single Point of Contact (SPOC) email and telephone line, for both current and former Service personnel who have concerns about their experience of mefloquine. Up to 15 January 2019, the mefloquine SPOC has received the following number of enquiries.<\/p> <\/p> Year<\/strong><\/p><\/td> Enquiries from Serving Personnel<\/strong><\/p><\/td> Enquiries from Veterans<\/strong><\/p><\/td> Enquiries from Others<\/strong><\/p><\/td> Total Number of Enquiries<\/strong><\/p><\/td><\/tr> 2016<\/strong><\/p><\/td> 24<\/p><\/td> 33<\/p><\/td> 22<\/p><\/td> 79<\/strong><\/p><\/td><\/tr> 2017<\/strong><\/p><\/td> 3<\/p><\/td> 10<\/p><\/td> 5<\/p><\/td> 18<\/strong><\/p><\/td><\/tr> 2018<\/strong><\/p><\/td> 4<\/p><\/td> 7<\/p><\/td> 6<\/p><\/td> 17<\/strong><\/p><\/td><\/tr> 2019<\/strong><\/p><\/td> 0<\/p><\/td> 1<\/p><\/td> 0<\/p><\/td> 1<\/strong><\/p><\/td><\/tr><\/tbody><\/table> <\/p> Individuals can be referred to the SPOC in a number of different ways, including by Service charities. The MOD does not maintain a record of all such referrals.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/1487", "label" : {"_value" : "Biography information for Mr Tobias Ellwood"}
}
, "answeringMemberConstituency" : {"_value" : "Bournemouth East"}
, "answeringMemberPrinted" : {"_value" : "Mr Tobias Ellwood"}
, "dateOfAnswer" : {"_value" : "2019-01-17", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "208186"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-01-17T16:17:08.923Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "11"}
, "answeringDeptShortName" : {"_value" : "Defence"}
, "answeringDeptSortName" : {"_value" : "Defence"}
, "date" : {"_value" : "2019-01-14", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Armed Forces: Mefloquine"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Defence, how many (a) service personnel and (b) veterans his Department has referred to the Mefloquine Single Point of Contact in each year since it\u2019s inception.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/252", "label" : {"_value" : "Biography information for Dr David Drew"}
}
, "tablingMemberConstituency" : {"_value" : "Stroud"}
, "tablingMemberPrinted" : [{"_value" : "Dr David Drew"}
], "uin" : "208187"}
, {"_about" : "http://data.parliament.uk/resources/1041262", "AnsweringBody" : [{"_value" : "Home Office"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1041262/answer", "answerText" : {"_value" : " Last year we launched a public consultation on the Government response to domestic abuse in which we asked about the risk of technology being used to perpetrate abuse.<\/p> We will be publishing a response to the consultation and draft Domestic Abuse Bill soon.<\/p> The Government will also shortly publish a white paper detailing how we will tackle online harms, including domestic abuse.<\/p> We have also provided Refuge with £250,000 of funding through the Tampon Tax to provide specialist nationwide support to staff and survivors who experience technologically facilitated abuse.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4399", "label" : {"_value" : "Biography information for Victoria Atkins"}
}
, "answeringMemberConstituency" : {"_value" : "Louth and Horncastle"}
, "answeringMemberPrinted" : {"_value" : "Victoria Atkins"}
, "dateOfAnswer" : {"_value" : "2019-01-17", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "208307"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-01-17T16:26:14.873Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "1"}
, "answeringDeptShortName" : {"_value" : "Home Office"}
, "answeringDeptSortName" : {"_value" : "Home Office"}
, "date" : {"_value" : "2019-01-14", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Domestic Abuse"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for the Home Department, what assessment he has made of the risks of smart home and internet-connected devices being used to enable domestic violence.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4621", "label" : {"_value" : "Biography information for Darren Jones"}
}
, "tablingMemberConstituency" : {"_value" : "Bristol North West"}
, "tablingMemberPrinted" : [{"_value" : "Darren Jones"}
], "uin" : "208306"}
, {"_about" : "http://data.parliament.uk/resources/1041263", "AnsweringBody" : [{"_value" : "Home Office"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1041263/answer", "answerText" : {"_value" : " Last year we launched a public consultation on the Government response to domestic abuse in which we asked about the risk of technology being used to perpetrate abuse.<\/p> We will be publishing a response to the consultation and draft Domestic Abuse Bill soon.<\/p> The Government will also shortly publish a white paper detailing how we will tackle online harms, including domestic abuse.<\/p> We have also provided Refuge with £250,000 of funding through the Tampon Tax to provide specialist nationwide support to staff and survivors who experience technologically facilitated abuse.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4399", "label" : {"_value" : "Biography information for Victoria Atkins"}
}
, "answeringMemberConstituency" : {"_value" : "Louth and Horncastle"}
, "answeringMemberPrinted" : {"_value" : "Victoria Atkins"}
, "dateOfAnswer" : {"_value" : "2019-01-17", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "208306"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-01-17T16:26:14.927Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "1"}
, "answeringDeptShortName" : {"_value" : "Home Office"}
, "answeringDeptSortName" : {"_value" : "Home Office"}
, "date" : {"_value" : "2019-01-14", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Domestic Abuse"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for the Home Department, what steps the Government is taking to prevent the misuse of smart home and internet-connected devices to enable domestic violence.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4621", "label" : {"_value" : "Biography information for Darren Jones"}
}
, "tablingMemberConstituency" : {"_value" : "Bristol North West"}
, "tablingMemberPrinted" : [{"_value" : "Darren Jones"}
], "uin" : "208307"}
, {"_about" : "http://data.parliament.uk/resources/1041268", "AnsweringBody" : [{"_value" : "Department for Work and Pensions"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1041268/answer", "answerText" : {"_value" : " Claimants only move from existing benefits to Universal Credit through natural migration when they experience a significant change in their circumstances that triggers a new claim to a benefit that Universal Credit replaces. Their entitlement is then calculated on the rules of their new benefit and their new circumstances. Transitional protection is designed to ensure those claimants who are moved onto Universal Credit without a change in circumstances receive the same level of entitlement to Universal Credit as they were entitled to on legacy benefits.<\/p> <\/p> As Universal Credit is simpler, the most recent estimates show that around 700,000 households will get entitlements they were not claiming under the legacy system, worth on average £285 per month.<\/p> <\/p> We have also introduced a number of measures to assist claimants during their transition to Universal Credit. Claimants who naturally migrate to Universal Credit can access a Universal Credit advance, which is worth up to 100 per cent of their indicative award and is available from the date of their claim. This advance is currently repayable over 12 months, but as announced in the 2018 Budget, from October 2021 the maximum repayment period will be extended to 16 months. Claimants may also be entitled to a two week Universal Credit Transitional Housing Payment. From July 2020 the Government is introducing a new two-week run on for income-related Employment and Support Allowance, Income Support and income-based Jobseeker\u2019s Allowance.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4014", "label" : {"_value" : "Biography information for Sir Alok Sharma"}
}
, "answeringMemberConstituency" : {"_value" : "Reading West"}
, "answeringMemberPrinted" : {"_value" : "Alok Sharma"}
, "dateOfAnswer" : {"_value" : "2019-01-17", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-01-17T17:05:50.31Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "29"}
, "answeringDeptShortName" : {"_value" : "Work and Pensions"}
, "answeringDeptSortName" : {"_value" : "Work and Pensions"}
, "date" : {"_value" : "2019-01-14", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Universal Credit"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Work and Pensions, whether her Department has plans to provide transitional protection to people that will naturally migrate to universal credit as a result of a change in circumstances.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4665", "label" : {"_value" : "Biography information for Laura Pidcock"}
}
, "tablingMemberConstituency" : {"_value" : "North West Durham"}
, "tablingMemberPrinted" : [{"_value" : "Laura Pidcock"}
], "uin" : "208310"}
], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=1&legislature.prefLabel=House+of+Commons&min-date=2018-11-14&answer.dateOfAnswer=2019-01-17&min-answer.questionFirstAnswered.=2019-01-17T15%3A55%3A08.957Z&max-date=2019-01-23", "page" : 0, "startIndex" : 1, "totalResults" : 147, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}
|